Skip to content

Type 1 diabetes — complications

TL;DR — Cumulative glycemic exposure is causal and modifiable: DCCT intensive therapy reduced retinopathy onset by 76%, microalbuminuria by 39%, and clinical neuropathy by 60%, though severe hypoglycemia rose two- to threefold (DCCT 1993, PMID 8366922). EDIC showed “metabolic memory”: early control produced later cardiovascular benefit even after HbA1c convergence (Nathan 2005, PMID 16371630; DCCT/EDIC 2016, PMID 26861924). Risk also reflects duration, age at onset, blood pressure, lipids, smoking, kidney disease, and social access; childhood onset carries especially high lifetime cardiovascular risk (Rawshani 2018, PMID 30129464). Screening detects treatable early disease but interval evidence is organ- and risk-specific.

DCCT/EDIC quantitative anchor

Outcome during DCCT Intensive-therapy effect Tradeoff
Retinopathy development 76% reduction More severe hypoglycemia
Retinopathy progression 54% reduction Greater treatment workload
Microalbuminuria 39% reduction Weight gain in trial era
Clinical neuropathy 60% reduction —

DCCT randomized 1,441 people with T1D and established the microvascular benefit of intensive insulin therapy (DCCT 1993, PMID 8366922). EDIC follow-up later found fewer cardiovascular events, supporting a durable legacy of earlier exposure (Nathan 2005, PMID 16371630; DCCT/EDIC 2016, PMID 26861924).

Organ-system map

Domain Early marker Clinical outcomes Modifiers/interventions
Retina Microaneurysms/photographic change Vision-threatening retinopathy Glycemia, BP, retinal treatment
Kidney Albuminuria and eGFR change Kidney failure, cardiovascular risk Glycemia, BP, renoprotective care
Nerve Sensory loss, autonomic dysfunction Ulcer, pain, gastroparesis Glycemia, foot protection
Cardiovascular Risk factors/subclinical disease MI, stroke, heart failure Lipids, BP, smoking, glycemia
Foot Neuropathy, deformity, vascular disease Ulcer, infection, amputation Inspection, footwear, urgent care
Eye lens Glycemic change/cataract Visual impairment Glycemic and ophthalmic care

Retinopathy

Screening schedules should reflect duration, prior retinal status, glycemia, pregnancy, and access. DCCT/EDIC modeling supports individualized intervals rather than assuming annual examination is equally efficient for every risk state (DCCT/EDIC Research Group 2017, PMID 28423305).

Rapid glycemic improvement can transiently worsen retinopathy in susceptible people even while long-term control is protective; this is a monitoring issue, not a reason to preserve chronic hyperglycemia.

Kidney disease

Albuminuria and eGFR convey overlapping but non-identical information. Persistent abnormal results require confirmation and attention to exercise, infection, menstruation, acute illness, and hemodynamic changes that can distort a single sample.

Kidney disease amplifies hypoglycemia through reduced insulin clearance and amplifies cardiovascular risk. Renal endpoints have changed across eras; microalbuminuria is not equivalent to kidney failure.

Neuropathy and foot disease

Distal symmetric polyneuropathy causes sensory loss and pain; autonomic involvement can affect cardiovascular responses, gastrointestinal function, bladder, sexual function, and hypoglycemia awareness. Foot risk emerges from interaction among neuropathy, pressure, deformity, vascular disease, and delayed wound recognition.

Cardiovascular disease and mortality

In EDIC, earlier intensive therapy reduced cardiovascular events after long follow-up (Nathan 2005, PMID 16371630; DCCT/EDIC 2016, PMID 26861924). Swedish registry analysis found onset before age 10 associated with HR 4.1 for all-cause death and roughly 30 for coronary heart disease versus controls, much higher than later-onset groups (Rawshani 2018, PMID 30129464).

Residual risk remains even at target HbA1c, showing that glycemia is necessary but not sufficient as a prevention strategy (Rawshani 2017, PMID 28402770).

Risk dimension Why HbA1c alone misses it
Blood pressure Independent vascular and kidney load
LDL/non-HDL cholesterol Atherosclerotic exposure
Smoking Vascular and cancer risk
Albuminuria/eGFR Strong cardiovascular and drug-safety marker
Glycemic variability/hypoglycemia Acute risk not captured by mean
Duration/age at onset Cumulative exposure clock
Socioeconomic access Determines treatment continuity and screening

DKA in established disease

DKA after diagnosis is usually precipitated by insulin interruption, illness, pump failure, access problems, or intentional omission. Youth registry data show coexistence of DKA and severe hypoglycemia risks (Cengiz 2013, PMID 23469984). Recurrent DKA is a systems signal requiring psychosocial and supply assessment, not merely re-education.

Metabolic memory and effect size

During DCCT, intensive therapy reduced retinopathy progression by 63%, severe nonproliferative retinopathy by 47%, microalbuminuria by 39%, macroalbuminuria by 54%, and clinical neuropathy by 60%. Each 10% proportional HbA1c reduction was associated with about 40% lower retinopathy-progression risk in both randomized groups (Genuth 2006, PMID 16627378). These relative effects arose in a selected trial cohort and should not be converted into individual absolute risk without duration and baseline-risk data.

The cardiovascular legacy effect emerged after randomized separation ended. Over mean 17-year follow-up, prior intensive therapy produced 46 cardiovascular events in 31 participants versus 98 in 52 controls: 42% lower risk of any cardiovascular event (95% CI 9–63) and 57% lower risk of MI, stroke, or cardiovascular death (12–79) (Nathan 2005, PMID 16371630).

Outcome Intensive-therapy effect Interpretation
Retinopathy progression −63% during DCCT Strong relative prevention effect
Microalbuminuria −39% Kidney benefit begins before GFR loss
Macroalbuminuria −54% Not all albuminuria is irreversible
Clinical neuropathy −60% Clinical endpoint, not all neuropathy phenotypes
Any cardiovascular event −42% (95% CI 9–63) long-term Delayed legacy effect
Foot ulcer over EDIC HR 0.77 (95% CI 0.60–0.97) Long-term extension to lower-extremity disease

Kidney trajectories are bidirectional

Among 325 DCCT/EDIC participants developing persistent microalbuminuria, ten-year cumulative incidence was 28% for macroalbuminuria, 15% for eGFR <60, 4% for end-stage kidney disease, and 40% for regression to normoalbuminuria (de Boer 2011, PMID 21403038). Microalbuminuria is therefore a risk state, not an inevitable staircase.

Among 159 who developed macroalbuminuria and were followed a median nine years, 52% regressed below 300 mg/day by ten years; 32% developed sustained eGFR <60 and 16% kidney failure. Lower HbA1c, lower blood pressure, and albuminuria regression predicted better GFR outcomes (de Boer 2014, PMID 24925722).

Marker Captures Misses
Urine albumin Glomerular injury/risk and treatment response Normoalbuminuric GFR loss
eGFR Filtration level and slope Early hyperfiltration and structural injury
Blood pressure Modifiable hemodynamic load Direct glycemic and inflammatory injury
Retinopathy Shared microvascular exposure Kidney-specific pathways

Retinopathy in contemporary care

Early disease can regress. In 113 adults with mild nonproliferative retinopathy under modern care, 57.5% regressed, 31.0% remained stable, and 11.5% progressed over about five years. Lower follow-up HbA1c independently predicted regression; correlated CGM metrics did not add prediction beyond HbA1c (Piñar-Gutiérrez 2026, PMID 42626886). This small retrospective cohort does not replace prospective screening-interval evidence.

Cardiovascular risk is declining but remains excessive

In a Finnish national childhood-onset cohort of 11,766 people followed a median 29.6 years, cardiovascular risk fell 3.8% for each later diagnosis year (HR 0.96, 95% CI 0.96–0.97). Yet those diagnosed in the 1990s retained standardized incidence ratios of 8.9 (3.9–17.5) for coronary disease and 2.9 (1.3–5.7) for stroke (Harjutsalo 2021, PMID 34303414).

Age at onset adds lifetime exposure. Compared with matched controls, diagnosis at age 0–10 carried HR 4.11 for all-cause mortality, 30.50 for coronary disease, 30.95 for MI, and 12.90 for heart failure; diagnosis at 26–30 carried lower but still elevated HRs of 2.83, 6.08, 5.77, and 5.07 respectively (Rawshani 2018, PMID 30129464).

Neuropathy, feet, and cognition

Over 23 EDIC years, former intensive therapy reduced all diabetic foot ulcers (HR 0.77, 95% CI 0.60–0.97); the amputation estimate was directionally similar but imprecise (HR 0.70, 0.36–1.36). Neuropathy and autonomic dysfunction predicted ulcers, while kidney disease, albuminuria, and macular edema predicted amputation (Boyko 2022, PMID 35007329).

Residual C-peptide after mean 35 years correlated with much less severe hypoglycemia but not lower advanced microvascular-complication rates (Gubitosi-Klug 2021, PMID 33529168). This separates a short-term protective phenotype from proven complication modification.

Associated autoimmune disease

A 180-study meta-analysis covering 293,889 people with T1D estimated hypothyroidism at 9.8% (95% CI 7.5–12.3), celiac disease 4.5% (4.0–5.5), gastric autoimmunity 4.3% (1.6–8.2), vitiligo 2.4% (1.2–3.9), hyperthyroidism 1.3% (0.9–1.8), and adrenal insufficiency 0.2% (0.0–0.4), with moderate-to-high heterogeneity (Nederstigt 2019, PMID 30508413).

Thyroid-autoimmunity-positive people had pooled risk ratio 25 (95% CI 9–71) for thyroid dysfunction, but a review of 14 prospective studies could not determine the optimal screening frequency and found no cost-effectiveness studies (Shun 2014, PMID 24103027). Guidelines recommending surveillance are therefore stronger on disease association than interval optimization.

Recurrent DKA as a prognostic marker

In 298 people accounting for 628 UK DKA admissions, inpatient mortality was ≤0.16%, but subsequent death risk was 5.2% after one admission versus 23.4% after recurrent admissions (HR 6.18). Recurrent cases were younger, more deprived, had median HbA1c 11.6% versus 9.4%, and used antidepressants more often (Gibb 2016, PMID 27397023).

A Brazilian cohort of 231 people hospitalized with DKA found five-year death probabilities 4.58% after one established-disease episode, 24.40% after 2–5, and 26.63% after >5; ≥2 episodes carried RR 4.49 (Santos 2023, PMID 37106409). These observational associations identify a high-risk systems phenotype rather than proving recurrent DKA itself causes death.

Complication inequity and competing outcomes

Black children in a 10,704-person US registry had higher HbA1c, DKA, and severe hypoglycemia than White or Hispanic children after measured socioeconomic adjustment (Willi 2015, PMID 25687140). Health utility in pediatric T1D was 0.90 (95% CI 0.88–0.92) with complications versus 0.96 (0.95–0.97) without, but came from six studies and mixed instruments (Xie 2024, PMID 37915225).

Pregnancy complications require pregnancy-specific evidence. An umbrella review estimated pre-eclampsia OR 4.19 (95% CI 3.08–5.71) in T1D, while heterogeneous autoimmune-disease reviews and observational inputs limit certainty (Singh 2023, PMID 37997130). Closed-loop pregnancy trials improve maternal glucose exposure, but are not yet powered to settle uncommon neonatal and maternal complication endpoints (Donovan 2025, PMID 41134589).

Open questions

  • Does sustained AID-era TIR reproduce DCCT’s long-term complication reduction, and what TIR dose-response applies? (Brown 2019, PMID 31618560)
  • Which mechanisms drive excess cardiovascular risk at guideline HbA1c? (Rawshani 2017, PMID 28402770)
  • Can screening intervals be individualized without increasing missed sight-threatening disease? (DCCT/EDIC 2017, PMID 28423305)
  • How should age at onset alter lifetime prevention intensity? (Rawshani 2018, PMID 30129464)

References

  1. DCCT Research Group. Effect of intensive treatment on long-term complications. N Engl J Med. 1993;329:977-986. PMID 8366922
  2. Nathan DM, et al. Intensive diabetes treatment and cardiovascular disease. N Engl J Med. 2005;353:2643-2653. PMID 16371630
  3. DCCT/EDIC Study Research Group. Intensive Diabetes Treatment and Cardiovascular Outcomes: 30-Year Follow-up. Diabetes Care. 2016. PMID 26861924
  4. DCCT/EDIC Research Group, et al. Frequency of Evidence-Based Screening for Retinopathy. N Engl J Med. 2017;376:1507-1516. PMID 28423305
  5. Rawshani A, et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. N Engl J Med. 2017. PMID 28402770
  6. Rawshani A, et al. Excess mortality and cardiovascular disease by age at onset. Lancet. 2018;392:477-486. PMID 30129464
  7. Cengiz E, et al. Severe hypoglycemia and DKA among youth in T1D Exchange. Pediatr Diabetes. 2013;14:447-454. PMID 23469984
  8. Brown SA, et al. Six-Month Randomized Trial of Closed-Loop Control. N Engl J Med. 2019;381:1707-1717. PMID 31618560
  9. Genuth S. Insights from DCCT/EDIC on intensive glycemic treatment and complications. Endocr Pract. 2006;12 Suppl 1:34-41. PMID 16627378
  10. de Boer IH, et al. Long-term renal outcomes after microalbuminuria in DCCT/EDIC. Arch Intern Med. 2011;171:412-420. PMID 21403038
  11. de Boer IH, et al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol. 2014;25:2342-2350. PMID 24925722
  12. Piñar-Gutiérrez A, et al. Natural History of Mild Non-Proliferative Retinopathy Under Contemporary Care. Diabetes Technol Ther. 2026. PMID 42626886
  13. Harjutsalo V, et al. Long-term population-based trends in cardiovascular disease in type 1 diabetes. Lancet Diabetes Endocrinol. 2021;9:575-585. PMID 34303414
  14. Boyko EJ, et al. Risk of Foot Ulcer and Lower-Extremity Amputation in DCCT/EDIC. Diabetes Care. 2022;45:357-364. PMID 35007329
  15. Gubitosi-Klug RA, et al. Residual β cell function in long-term type 1 diabetes and hypoglycemia. J Clin Invest. 2021;131. PMID 33529168
  16. Nederstigt C, et al. Associated auto-immune disease in type 1 diabetes: systematic review and meta-analysis. Eur J Endocrinol. 2019;180:135-144. PMID 30508413
  17. Shun CB, et al. Thyroid autoimmunity in Type 1 diabetes: systematic review and meta-analysis. Diabet Med. 2014;31:126-135. PMID 24103027
  18. Gibb FW, et al. Risk of death following admission with diabetic ketoacidosis. Diabetologia. 2016;59:2082-2087. PMID 27397023
  19. Santos SS, et al. Increased risk of death following recurrent ketoacidosis admissions. Diabetol Metab Syndr. 2023;15:85. PMID 37106409
  20. Willi SM, et al. Racial-ethnic disparities in management and outcomes among children with type 1 diabetes. Pediatrics. 2015;135:424-434. PMID 25687140
  21. Xie S, et al. Health state utility values for children and adolescents with type 1 diabetes. Diabet Med. 2024;41:e15251. PMID 37915225
  22. Singh M, et al. Autoimmune diseases and adverse pregnancy outcomes: an umbrella review. Lancet. 2023;402 Suppl 1:S84. PMID 37997130
  23. Donovan LE, et al. Closed-Loop Insulin Delivery in Type 1 Diabetes in Pregnancy. JAMA. 2025;334:2176-2185. PMID 41134589
  24. Zammitt NN, et al. Predictors of impaired awareness and severe hypoglycaemia. Diabet Med. 2025;42:e70074. PMID 40386839
  25. Chauhan R, et al. Epidemiological and clinical insights from Type 1 Diabetes Global Registries. Diabetes Metab Syndr. 2026;20:103455. PMID 42551241